Glaukos has unveiled a new single-use surgical gonioscopy lens that is said to provide exceptional clarity with expanded views of angle structures. Read more
Is cannabis a treatment for glaucoma?
Medicinal cannabis is often presented as an alternative treatment for glaucoma. Although there is evidence that cannabis lowers intraocular pressure, its role as a viable glaucoma therapy is limited by a short duration of action, psychotropic effects, and possible tachyphylaxis.
RANZCO updates AMD referral pathway for optometrists
Professor Robyn Guymer has led an expert panel to update RANZCO’s Referral Pathway for Age-Related Macular Degeneration (AMD) Management, which accounts for greater accessibility to retinal imaging equipment and reminds clinicians to be aware of nearby clinical trials. Read more
Myopia Profile and CORE join forces
The world’s largest childhood myopia education resource developed by Australian optometry couple Dr Kate and Dr Paul Gifford has formed a new alliance with the renowned Centre for Ocular Research & Education (CORE). Read more
Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange
Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ahead of pivotal Phase 3 trials of its lead drug candidate. Read more
Aussie-developed glaucoma implant performs well in initial trial
A Victorian biopharmaceutical company has reported positive results from a Phase 1 study examining the safety of its biodegradable implant for glaucoma. Read more
Twin licensing deals bolster Bausch + Lomb’s myopia portfolio
Bausch + Lomb has acquired an exclusive license for a novel myopia control contact lens developed by a Sydney ophthalmic research institute, just days after signing another deal to commercialise an investigational microdose formulation of atropine. Read more
Campaign targets Aussies in their 50s at risk of AMD
Australian of the Year and ophthalmologist Dr James Muecke has endorsed a new campaign aimed at motivating Australians in their 50s to have a macula check after it was revealed most in this age group are unable to identify macular disease risk factors. Read more
Aussie firm introduces NovaTears +Omega-3 eye drop
ASX-listed AFT Pharmaceuticals has expanded its therapeutics range with a new dry eye therapy containing Omega-3. Read more
Glaucoma treatments change hands under pharmaceutical merger
A proposed merger between two pharmaceutical companies that compete in the glaucoma treatment markets has been given the green light – with one major stipulation. Read more